STATEN ISLAND, N.Y., July 1, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics ...
That's one of the most devastating statements a survivor can receive after the grueling journey of treatments, loneliness, and uncertainty that come with a cancer diagnosis. Sadly, the threat of a ...
We are in the midst of an unstructured data revolution – with 80% of data likely to be unstructured by 2025, according to IDC. The rise of advanced analytics and in particular artificial ...
A total of 23 studies from 11 registries in eight countries spanning Europe, North America, and Oceania were identified and included in the review. Most studies were retrospective in nature and ...
Our scalable NLP system enabled us to generate real-world insights into NSCLC recurrences, paving the way for predictive models for preventing, diagnosing, and treating NSCLC recurrence. Our NLP ...
Poster published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting shows the final 5 year safety data from the Phase IIb breast cancer clinical trial. Final safety conclusions ...
Nephrolithiasis is one of the most common conditions affecting the kidney and is characterized by a high risk of recurrence. Thiazide diuretic agents are widely used for prevention of the recurrence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback